Back to Search Start Over

Thrombin induces a temporal biphasic vascular response through the differential phosphorylation of endothelial nitric oxide synthase via protease-activated receptor-1 and protein kinase C.

Authors :
Okamura A
Miake J
Tomomori T
Takami A
Sawano T
Kato M
Ogura K
Tsujimoto D
Kawatani S
Agung KP
Notsu T
Hisatome I
Yamamoto K
Imamura T
Source :
Journal of pharmacological sciences [J Pharmacol Sci] 2022 Apr; Vol. 148 (4), pp. 351-357. Date of Electronic Publication: 2022 Feb 11.
Publication Year :
2022

Abstract

Endothelial nitric oxide synthase (eNOS) is a critical regulatory enzyme that controls vascular tone via the production of nitric oxide. Although thrombin also modulates vascular tone predominantly via the activation of protease-activated receptors (PARs), the time course and mechanisms involved in how thrombin controls eNOS enzymatic activity are unknown. eNOS enzymatic activity is enhanced by the phosphorylation of eNOS-Ser1177 and reduced by the phosphorylation of eNOS-Thr495. In this study, we hypothesized that thrombin regulates vascular tone through the differential phosphorylation of eNOS. Using rat descending aorta, we show that thrombin modulates vascular tone in an eNOS-dependent manner via activated PAR-1. We also show that thrombin causes a temporal biphasic response. Protein kinase C (PKC) is associated with second phase of thrombin-induced response. Western blot analysis demonstrated thrombin phosphorylated eNOS-Ser1177 and eNOS-Thr495 in human umbilical vein endothelial cells. A PKC inhibitor suppressed the thrombin-induced phosphorylation of eNOS-Thr495, but not that of eNOS-Ser1177. Our results suggest that thrombin induces a temporal biphasic vascular response through the differential phosphorylation of eNOS via activated PAR-1. Thrombin causes transient vasorelaxation by the phosphorylation of eNOS-Ser1177, and subsequent attenuation of vasorelaxation by the phosphorylation of eNOS-Thr495 via PKC, leading to the modulation of vascular tone.<br />Competing Interests: Declaration of competing interest The authors indicated no potential conflicts of interest.<br /> (Copyright © 2022 The Authors. Production and hosting by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1347-8648
Volume :
148
Issue :
4
Database :
MEDLINE
Journal :
Journal of pharmacological sciences
Publication Type :
Academic Journal
Accession number :
35300809
Full Text :
https://doi.org/10.1016/j.jphs.2022.02.001